Formula I KIF18A Inhibitors Targeting Mitotic Spindle Dynamics
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments have limited effectiveness, and KIF18A, a kinesin protein overexpressed in various cancers, presents a promising target for inhibiting unchecked cell proliferation and mitotic progression, but effective inhibitors are lacking.
Innovation Solution
Development of compounds that modulate and inhibit KIF18A activity, including pharmaceutical compositions for treating KIF18A-mediated diseases such as cancer, by targeting the KIF18A protein or its complex with microtubules.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current cancer treatments are used, then existing therapy options are available, but treatment effectiveness is limited
Solution Approach 1:
The patent introduces a novel class of compounds with specific chemical structures (Formula I) that represent a parameter change in therapeutic agents. These compounds target KIF18A with a mechanism of action different from existing cancer treatments, thereby improving treatment effectiveness while adding versatility to therapy options
Solution Approach 2:
The invention describes compounds comprising multiple structural components (heterocyclic ring, substituent groups R1-R14) that work together to achieve KIF18A inhibition. This composite molecular structure enables selective binding to the kinesin protein, providing both reliability and adaptability in cancer treatment
2Productivity
If KIF18A is inhibited, then cell proliferation is reduced, but specific inhibitors are lacking
Solution Approach 1:
The KIF18A inhibitor compounds are designed with segmented structural elements including a core heterocyclic ring (pyridine, pyrimidine, or picoline) with distinct substituent positions (R1-R14). This segmentation allows for systematic optimization of inhibitory activity while facilitating manufacturing through modular synthesis approaches
Solution Approach 2:
The patent systematically varies chemical parameters (different heterocyclic cores, various substituent groups, stereochemistry) to optimize KIF18A inhibition while maintaining ease of manufacture. The defined structural framework with specific variable positions enables scalable production of multiple analogs
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively induce mitotic cell arrest and apoptosis in cancer cells, providing a novel approach to treat various types of cancer by inhibiting KIF18A, thereby reducing tumor size and cell proliferation.
Implementation Method 1
Kinesins use the energy of ATP hydrolysis to move cargo along polarized microtubules
Implementation Method 2
KIF18A is believed to influence dynamics at the plus end of kinetochore microtubules to control correct chromosome positioning and spindle tension
Implementation Method 3
inhibition of KIF18A has been found to induce mitotic cell arrest, a known vulnerability that can promote cell death in mitosis via apoptosis, mitotic catastrophe, or multipolarity driven lethality
Data Source
AI summary
The present invention relates to chemical compounds having a general formula (I), as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.